Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Betabioptal is a fixed-dose combination ophthalmic medication containing the corticosteroid betamethasone and the broad-spectrum antibiotic chloramphenicol. It is formulated as eye drops, gel, or ointment for the treatment of non-purulent inflammatory conditions of the eye where a bacterial infection is present or suspected. Betamethasone acts as a potent anti-inflammatory agent by binding to glucocorticoid receptors and modulating gene expression to reduce the production of inflammatory mediators. Chloramphenicol provides antimicrobial coverage by binding to the 50S subunit of bacterial ribosomes, thereby inhibiting peptidyl transferase activity and protein synthesis. The drug is commonly used to manage post-operative inflammation following cataract surgery and to treat conditions such as bacterial conjunctivitis and iridocyclitis. It is primarily marketed in Europe by Thea Farma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on betamethasone + chloramphenicol.